skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: High Efficacy and Drug Synergy of HDAC6-Selective Inhibitor NN-429 in Natural Killer (NK)/T-Cell Lym

Journal Article · · Pharmaceutics
DOI:· OSTI ID:1901194

Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Organization:
DOE - Office Of Science; NIGMS
Journal Information:
Pharmaceutics, Vol. 15, Issue (11)
Country of Publication:
United States

References (61)

Treatment of localized extranodal NK/T cell lymphoma, nasal type: a systematic review journal December 2018
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone journal January 2009
Hepatosplenic T-cell Lymphoma: a review of clinicopathologic features, pathogenesis, and prognostic factors journal April 2018
NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model journal July 2018
The Diverse Roles of γδ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma journal December 2021
The Genetic Basis of Hepatosplenic T-cell Lymphoma journal April 2017
A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories journal July 2004
Hepatosplenic    T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients journal December 2003
Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia journal June 2021
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL journal February 2018
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia journal June 2015
Recent advances in small molecular modulators targeting histone deacetylase 6 journal October 2020
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight journal July 2020
HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions journal March 2007
HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination journal August 2007
HDAC6 is a microtubule-associated deacetylase journal May 2002
Drugging the HDAC6–HSP90 interplay in malignant cells journal October 2014
Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation journal April 2003
HDAC6-selective inhibitors decrease nerve-injury and inflammation-associated mechanical hypersensitivity in mice journal May 2020
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs? journal January 2013
The Role of HDAC6 in Cancer journal January 2011
Class II Histone Deacetylases: from Sequence to Function, Regulation, and Clinical Implication journal April 2005
Hydroxamic Acid Derivatives: From Synthetic Strategies to Medicinal Chemistry Applications journal August 2021
Hydroxamic Acids as Pharmacological Agents journal September 2002
Methods for Hydroxamic Acid Synthesis journal July 2019
Discovery of HDAC6-Selective Inhibitor NN-390 with in Vitro Efficacy in Group 3 Medulloblastoma journal February 2022
Unique Molecular Interaction with the Histone Deacetylase 6 Catalytic Tunnel: Crystallographic and Biological Characterization of a Model Chemotype journal February 2021
Quantitative, Real-Time Measurements of Intracellular Target Engagement Using Energy Transfer book December 2018
NanoBRET—A Novel BRET Platform for the Analysis of Protein–Protein Interactions journal June 2015
Targeting the cancer kinome through polypharmacology journal February 2010
Combinatorial drug therapy for cancer in the post-genomic era journal July 2012
Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs journal July 2019
Prospects for combining targeted and conventional cancer therapy with immunotherapy journal March 2017
SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy journal February 2020
SynergyFinder: a web application for analyzing drug combination dose–response matrix data journal March 2020
Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies journal June 2014
The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor journal October 2007
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors journal July 2010
Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model journal May 2017
Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug journal January 2007
Clinical Toxicities of Histone Deacetylase Inhibitors journal August 2010
Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology journal January 2019
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors journal May 2021
A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST). journal May 2018
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial journal November 2016
Selective Histone Deacetylase Inhibitor ACY-241 (Citarinostat) Plus Nivolumab in Advanced Non-Small Cell Lung Cancer: Results From a Phase Ib Study journal September 2021
Selective HDAC inhibition by ACY-241 enhances the activity of paclitaxel in solid tumor models journal December 2016
Enhancement of pomalidomide anti-tumor response with ACY-241, a selective HDAC6 inhibitor journal March 2017
Therapeutic potential of CKD-506, a novel selective histone deacetylase 6 inhibitor, in a murine model of rheumatoid arthritis journal July 2020
A novel histone deacetylase 6 inhibitor improves myelination of Schwann cells in a model of Charcot–Marie–Tooth disease type 1A journal September 2020
xia2 : an expert system for macromolecular crystallography data reduction journal December 2009
Phaser crystallographic software journal July 2007
Use of knowledge-based restraints in phenix.refine to improve macromolecular refinement at low resolution journal March 2012
Bulk-solvent and overall scaling revisited: faster calculations, improved results journal March 2013
Automatic multiple-zone rigid-body refinement with a large convergence radius journal July 2009
Features and development of Coot journal March 2010
Towards automated crystallographic structure refinement with phenix.refine journal March 2012
MolProbity : all-atom structure validation for macromolecular crystallography journal December 2009
A functional in vitro assay for screening inhibitors of STAT5B phosphorylation journal January 2019
PTG-0861: A novel HDAC6-selective inhibitor as a therapeutic strategy in acute myeloid leukaemia journal September 2020
Development of a fluorescence polarization based assay for histone deacetylase ligand discovery journal May 2008

Similar Records

Clinical significance of cyclooxygenase-2 expression in extranodal natural killer (NK)/T-cell lymphoma, nasal type
Journal Article · 2007 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:1901194

Effects of X-ray irradiation on natural killer (NK) cell system. I. Elevation of sensitivity of tumor cells and lytic function of NK cells
Journal Article · 1989 · Immunopharmacology and Immunotoxicology; (USA) · OSTI ID:1901194

Effects of X-ray irradiation on natural killer (NK) cell system. II. Increased sensitivity to natural killer cytotoxic factor (NKCF)
Journal Article · 1989 · Immunopharmacology and Immunotoxicology; (USA) · OSTI ID:1901194

Related Subjects